• Model NO.: Spiral Fin Tubes
  • Customized: Customized
  • Fuel: Coal
  • Type: Pressure Parts
  • Classification: Finned Tube, Spiral Tube
  • Application: Heat Exchanger Tubes
  • Lead Time: 30-60 Days
  • Trademark: HTEG
  • Specification: Customized size
  • HS Code: 8402119000
  • Certification: ISO
  • Surface Treatment: Painted
  • Range of Applications: Power station, Industrial
  • Name: Carbon Steel Spiral Fin Tubes for Economizer, Heat
  • Function: Heat Exchanger
  • Material: Carbon Steel, Alloy Steel or Equivalent
  • Port: Qingdao Port
  • Transport Package: Seaworthy Packing
  • Origin: Shandong, China

Carbon Steel Spiral Fin Tubes for Economizer
Introduction 

We can manufacture highfrequency welded spiral fin tubes  heater exchanger which are widely applied in electricity, petroleum, chemicals, and pharmacy industry. For example, economizer, air preheater, steam air heater, gas heater, liquid heater, steam heater, cooler, and flue gas heater.

The spiral fin tube economzier is a newly type heat transfer equipment, consisting of spiral fin tubes to overcome the serious abrasion and short service time.

Structure: consisted of a series of spiral finned tubes, the headers of inlet and outlet, bend, frame and other auxiliaries

Structure arrangement: in line/staggered arrangement
Carbon Steel Spiral Fin Tubes for Economizer
Technical specifications
High-frequency welded helical finned tube is a highly efficient heat transfer component, it consists of steel fins wrapped helically around steel pipe, and continuously welded using the high frequency electric current welding process so as to reduce the flow resistance and the metal consumpition, improve the efficiency of heat transfer equipment and operating reliability.

The heat transfer energy is more than 6-10times higher than the bare tubes.

Tube material: seamless steel, carbon steel

Fin Material: Carbon steel; stainless steel

Spiral fin tube specifications Unit: mm
Base tube OD 25-159
Base tube wall  thickness  2-8
Fin thickness 0.8-2
Fin height 10-30
Fin tube pitch 5-20
Fin tube length ≤1000
 

Accessories  and detailed pictures: 
Carbon Steel Spiral Fin Tubes for Economizer

Description : 

High frequency welded spiral fin tubes are made by high frequency welding crabon steel or ND steel belt  to the  carbon steel or ND steel . tubes. ND steel spiral steel is better than cabon steel spiral tubes in terms of corrosion resistance. So ND steel spiral tubes are maind applied for heat exchanger under environment expposed to corrosion. 
Application
Main technical advantages of our low temperature economizer 

1. The equipment body can be designed into many modules  to ensure the long term and stable running;

2. The low temperature economizer manufatured by our company can guarantee the wall temperature is 5-10 ºC higher than the acid , and flue outlet temperature is 10-15 ºC higher than the wall surface temperature

3. Wall surface temperature can be adjusted according to the boiler load and fuel changer to avoird corrosion under low temperature 

4. Changer the DCS system of the existing boiler to achieve the auto and remote control by computer 

Carbon Steel Spiral Fin Tubes for Economizer

Our company 
Shandong Hengtao Group, founded in 1995, is located in Gaomi City, Shandong Province. Hengtao Group has 470,000,000 RMB of total registered capital, 1,400,000 square meter of land coverage, about 2000 employees and over 3 billion RMB of total assets. 

Our Products: utility boiler, biomass boiler, heat recovery boiler and boiler parts, such as enamel tube air preheater, low temperature economizer, water wall, super heater and header, etc.
Customer visit and certificates
Carbon Steel Spiral Fin Tubes for Economizer

We have ISO 9001, ISO 14001 certificates.
We conform to ASME standard.



 

Baricitinib Intermediates

Baricitinib is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, baricitinib binds to JAK1/2, which inhibits JAK1/2 activation and leads to the inhibition of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This decreases the production of inflammatory cytokines and may prevent an inflammatory response. In addition, baricitinib may induce apoptosis and reduce proliferation of JAK1/2-expressing tumor cells. JAK kinases are intracellular enzymes involved in cytokine signaling, inflammation, immune function and hematopoiesis; they are also upregulated and/or mutated in various tumor cell types.

Baricitinib is an orally available small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis and more recently was given emergency use authorization as therapy in combination with remdesivir for severe COVID-19. Baricitinib is associated with transient and usually mild elevations in serum aminotransferase levels during therapy but has yet to be linked to cases of clinically apparent acute liver injury.

Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family and play an important role in the proinflammatory pathway signalling that is frequently over-activated in autoimmune disorders such as rheumatoid arthritis. By blocking the actions of JAK1/2, baricitinib disrupts the activation of downstream signalling molecules and proinflammatory mediators. Rheumatoid arthritis is a progressive autoimmune disease commonly associated with discomfort, diasability, and joint damage. Throughout disease progression, the disease may further lead to joint erosions and deformities, causing premature mortality, functional impairment, and reduced quality of life. While there are several disease modifying antirheumatic drugs (DMARDs) available for treatment, patients often experience inadequate threapeutic resposes to these drugs. In animal models of inflammatory arthritis, baricitinib was shown to have significant anti-inflammatory effects, but also led to preservation of cartilage and bone, with no detectable suppression of humoral immunity or adverse hematologic effects. In the EU, baricitinib was approved in February of 2017 as a second-line orally administered treatment for moderate to severe active rheumatoid arthritis in adults, either as a monotherapy or when combined with methotrexate. It is marketed under the trade name Olumiant. Baricitinib in combination with [remdesivir] for the treatment of COVID-19, was granted an FDA Emergency Use Authorization on 19 November 2020.

Baricitinib is an oral inhibitor of JAK kinase 1 and 2. It is commonly used in adults to treat moderate to severe active chemicalbook rheumatoid arthritis (RA). For patients with rheumatoid arthritis who have not previously used biological DMARDs drugs, barrictinib can reduce the activity of the disease.


Professional Baricitinib Cas 269410-08-4,Baricitinib Cas 1029716-44-6,Baricitinib Cas 1187595-85-2,Baricitinib Cas 941685-26-3,Baricitinib Cas 941685-27-4,Baricitinib Cas 1187594-09-7,etc.

Baricitinib Cas 269410-08-4,Baricitinib Cas 1029716-44-6,Baricitinib Cas 1187595-85-2,Baricitinib Cas 941685-26-3,Baricitinib Cas 941685-27-4,Baricitinib Cas 1187594-09-7

 Shandong Haohong Biotechnology Co., Ltd. , https://www.haohongpharma.com